« Return to News | CROs/Service Providers

Kendle to Open Third Office in India

Wednesday, March 10, 2010 06:54 AM

Kendle plans to open a new facility in India by the middle of April. The new unit will be based in a Special Economic Zone (SEZ) in the upcoming Ahmedabad-Gandhinagar Knowledge Corridor. The Indian government has established SEZs throughout the country to increase foreign investment and business.

Kendle already has offices in Ahmedabad and New Delhi. The contract research organization (CRO) will initially employ 50 people at the SEZ operations center with room to grow to up to 300. The company will offer the following services at the new facility: clinical data management, medical writing, pharmacovigilance/safety, biostatistics/programming and other knowledge processing-related services.  

"Continued expansion throughout the Asia/Pacific region is crucial to the future growth of Kendle," said Stephen Cutler, Ph.D., senior vice president and chief operating officer, in a statement. "Our increased capacity in the region will allow us to better meet the growing demands of our customers who are seeking to capitalize on India's rapidly expanding high-quality biopharmaceutical capabilities.”

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.